VIDEO: ‘Very busy pipeline’ in atopic dermatitis

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So in the pipeline, we have the OX40-OX40 ligand antagonist and these are touching upon that exact idea of disease modification, because early studies show that, when you stop the drug, you may not have recurrence for quite some time. So it depends how long will be that time and probably it will mean for our patients that they can inject much less frequently, similar to psoriasis, and that's another form of disease modification.

And then, there are some treatments going after T-regs, T-regulatory cells, including IL-2 mutein and the others. Also, very interesting, there is a CCR4 antagonist. It's kind of the same pathway like the OX-40s. Very exciting time there, and there is another IL-13 that is almost about to be approved or we are anticipating it really literally any day.

That's lebrikizumab that showed great data as well. There are also, a little bit earlier in the pipeline, but very exciting, oral STAT-6 that is kind of think about it like an oral dupilumab. We have also topicals that are exciting, anti PD-4, JAK-1, JAK-2. We have another one coming that is a pan JAK and we have a tapinarof that is an AhR agonist. Many, many things coming, a very busy pipeline, and very exciting times.